These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23021245)

  • 1. Chapter six--Adenovirus-based immunotherapy of cancer: promises to keep.
    de Gruijl TD; van de Ven R
    Adv Cancer Res; 2012; 115():147-220. PubMed ID: 23021245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.
    Cerullo V; Koski A; Vähä-Koskela M; Hemminki A
    Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chapter four--Design of improved oncolytic adenoviruses.
    Alemany R
    Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy.
    Tosch C; Geist M; Ledoux C; Ziller-Remi C; Paul S; Erbs P; Corvaia N; Von Hoegen P; Balloul JM; Haegel H
    Cancer Gene Ther; 2009 Apr; 16(4):310-9. PubMed ID: 18949016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells.
    Liljenfeldt L; Yu D; Chen L; Essand M; Mangsbo SM
    J Immunother; 2014 Apr; 37(3):155-62. PubMed ID: 24598450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35.
    Sakurai F; Nakashima K; Yamaguchi T; Ichinose T; Kawabata K; Hayakawa T; Mizuguchi H
    J Control Release; 2010 Dec; 148(2):212-8. PubMed ID: 20800630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
    Bernt KM; Ni S; Tieu AT; Lieber A
    Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.
    Seregin SS; Amalfitano A
    Expert Opin Biol Ther; 2009 Dec; 9(12):1521-31. PubMed ID: 19780714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
    Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.
    Clarke JM; Morse MA; Lyerly HK; Clay T; Osada T
    Expert Opin Biol Ther; 2010 Jun; 10(6):875-83. PubMed ID: 20380487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
    Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
    Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poxviruses as vectors for cancer immunotherapy.
    Kwak H; Hörig H; Kaufman HL
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
    Liu Y; Xia D; Li F; Zheng C; Xiang J
    Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic HSV as a vector in cancer immunotherapy.
    Li H; Zhang X
    Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GM-CSF-armed, replication-competent viruses for cancer.
    Burke JM
    Cytokine Growth Factor Rev; 2010; 21(2-3):149-51. PubMed ID: 20381405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.